Generation of the Human Metabolite Piceatannol from the Anticancer-Preventive Agent Resveratrol by Bacterial Cytochrome P450 BM3

In recent studies, the wild-type and mutant forms of cytochrome P450 (P450) BM3 (CYP102A1) from Bacillus megaterium were found to metabolize various drugs through reactions similar to those catalyzed by human P450 enzymes. Therefore, it was suggested that CYP102A1 can be used to produce large quantities of the metabolites of human P450-catalyzed reactions. trans-Resveratrol (3,4′,5-trihydroxystilbene), an anticancer-preventive agent, is oxidized by human P450 1A2 to produce two major metabolites, piceatannol (3,5,3′,4′-tetrahydroxystilbene) and another hydroxylated product. In this report, we show that the oxidation of trans-resveratrol, a human P450 1A2 substrate, is catalyzed by wild-type and a set of CYP102A1 mutants. One major hydroxylated product, piceatannol, was produced as a result of the hydroxylation reaction. Other hydroxylated products were not produced. Piceatannol formation was confirmed by high-performance liquid chromatography and gas chromatograph-mass spectrometry by comparing the metabolite with the authentic piceatannol compound. These results demonstrate that CYP102A1 mutants can be used to produce piceatannol, a human metabolite of resveratrol.

[1]  H. Cho,et al.  Piceatannol, a stilbene present in grapes, attenuates dextran sulfate sodium-induced colitis. , 2008, International immunopharmacology.

[2]  Kwang-Hyeon Liu,et al.  Generation of Human Metabolites of 7-Ethoxycoumarin by Bacterial Cytochrome P450 BM3 , 2008, Drug Metabolism and Disposition.

[3]  J. K. Kundu,et al.  Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. , 2008, Cancer letters.

[4]  L. Pirola,et al.  Resveratrol: One molecule, many targets , 2008, IUBMB life.

[5]  N. Vermeulen,et al.  Structural rationalization of novel drug metabolizing mutants of cytochrome P450 BM3 , 2008, Proteins.

[6]  D. Fairman,et al.  Progress Curve Analysis of CYP1A2 Inhibition: A More Informative Approach to the Assessment of Mechanism-Based Inactivation? , 2007, Drug Metabolism and Disposition.

[7]  L. Kopelovich,et al.  Resveratrol: a review of preclinical studies for human cancer prevention. , 2007, Toxicology and applied pharmacology.

[8]  Heung-Chae Jung,et al.  The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. , 2007, Trends in biotechnology.

[9]  G. Gilardi,et al.  Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes , 2007, JBIC Journal of Biological Inorganic Chemistry.

[10]  R. Bernhardt,et al.  Cytochromes P450 as versatile biocatalysts. , 2006, Journal of biotechnology.

[11]  T. Ahn,et al.  Functional expression of human cytochrome P450 enzymes in Escherichia coli. , 2006, Current drug metabolism.

[12]  W. Baer-Dubowska,et al.  Effect of natural analogues of trans-resveratrol on cytochromes P4501A2 and 2E1 catalytic activities , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  F. Arnold,et al.  Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450. , 2006, Biotechnology and bioengineering.

[14]  U. Stottmeister,et al.  White biotechnology for green chemistry: fermentative 2-oxocarboxylic acids as novel building blocks for subsequent chemical syntheses , 2005, Journal of Industrial Microbiology and Biotechnology.

[15]  Imad Hanna,et al.  Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli , 2005, Journal of Industrial Microbiology and Biotechnology.

[16]  F. Berthou,et al.  Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. , 2004, Biochemical pharmacology.

[17]  T. Skaar,et al.  Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen , 2004, Breast Cancer Research and Treatment.

[18]  P. Farmer,et al.  The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1 , 2002, British Journal of Cancer.

[19]  F. Guengerich,et al.  A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. , 2001, Cancer research.

[20]  R D Schmid,et al.  Rational evolution of a medium chain-specific cytochrome P-450 BM-3 variant. , 2001, Biochimica et biophysica acta.

[21]  T. Rushmore,et al.  Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites. , 2000, Metabolic engineering.

[22]  F. Guengerich,et al.  Resveratrol is a selective human cytochrome P450 1A1 inhibitor. , 1999, Biochemical and biophysical research communications.

[23]  F. Guengerich,et al.  Drug metabolism by Escherichia coli expressing human cytochromes P450 , 1997, Nature Biotechnology.

[24]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES. , 1964, The Journal of biological chemistry.

[25]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[26]  F. Guengerich,et al.  New applications of bacterial systems to problems in toxicology. , 1996, Critical reviews in toxicology.